Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases

Cancer Research

Volumn 76, Issue 2, 2016, Pages 429-439

  Tanei, Tomonori ^a   Leonard, Fransisca ^a   Liu, Xuewu ^a   Alexander, Jenolyn F ^a   Saito, Yuki ^a   Ferrari, Mauro ^a   Godin, Biana ^a   Yokoi, Kenji ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; DRUG TRANSPORT; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIVER METASTASIS; LUNG CANCER; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; LIVER; LIVER NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY;

ALBUMIN-BOUND PACLITAXEL; ANIMALS; CELL PROLIFERATION; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASM METASTASIS;

EID: 84958998849     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1576     Document Type: Article

References (47)

1. Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. J Breast Cancer 2013;16: 184-92.
2. Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA. Liver metastases from breast cancer: long-term survival after curative resection. Surgery 2000;127:383-9.
3. Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer 2015;88:187-94.
4. Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, et al. Pattern ofmetastasis and outcome in patients with breast cancer. Clin Exp Metastasis 2015;32:125-33.
5. Michor F, Liphardt J, FerrariM,Widom J. What does physics have to do with cancer? Nat Rev Cancer 2011;11:657-70.
6. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 2014;124:1525-36.
7. Pezzella F, PastorinoU, Tagliabue E, Andreola S, Sozzi G, GaspariniG, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997;151:1417-23.
8. Stessels F, Van Den Eynden G, Van Der Auwera I, Salgado R, Van Den Heuvel E, Harris AL, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 2004;90:1429-36.
9. Daly JM, Butler J, Kemeny N, Yeh SD, Ridge JA, Botet J, et al. Predicting tumor response in patients with colorectal hepatic metastases. Ann Surg 1985;202:384-93.
10. Yokoi K, Tanei T, Godin B, van de Ven AL, Hanibuchi M, Matsunoki A, et al. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Lett 2014; 345:48-55.
11. Baratta JL, Ngo A, Lopez B, Kasabwalla N, Longmuir KJ, Robertson RT. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. Histochem Cell Biol 2009;131:713-26.
12. Heuff G, van der Ende MB, Boutkan H, Prevoo W, Bayon LG, Fleuren GJ, et al. Macrophage populations in different stages of induced hepatic metastases in rats: an immunohistochemical analysis. Scand J Immunol 1993;38:10-6.
13. Reimer P, Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 1998;8:1198-204.
14. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 2008;3:151-7.
15. Sakamoto J, Annapragada A, Decuzzi P, Ferrari M. Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv 2007;4:359-69.
16. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta 2011;1810:317-29.
17. Godin B, Chiappini C, Srinivasan S, Alexander JF, Yokoi K, Ferrari M, et al. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv Funct Mater 2012;22:4225-35.
18. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011;44:979-89.
19. Tanaka T, Godin B, Bhavane R, Nieves-Alicea R, Gu J, Liu X, et al. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm 2010; 402:190-7.
20. Yokoi K, Godin B, Oborn CJ, Alexander JF, Liu X, Fidler IJ, et al. Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Lett 2013;334:319-27.
21. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-96.
22. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V,Mai J, Huang Y, et al. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res 2013;19:1806-15.
23. Blanco E, Sangai T, Hsiao A, Ferrati S, Bai L, Liu X, et al. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 2012;334:245-52.
24. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24.
25. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6.
26. Godin B, GuJ, Serda RE, Bhavane R, Tasciotti E, Chiappini C, et al. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A 2010;94:1236-43.
27. Leonard F, Margulis-Goshen K, Liu X, Srinivasan S, Magdassi S, Godin B. Low pressure mediated enhancement of nanoparticle and macromolecule loading into porous silicon structures. Mesoporous Biomater 2014;1: 10.2478/mesbi-014-0002.
28. Tasciotti E, Godin B, Martinez JO, Chiappini C, Bhavane R, Liu X, et al. Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging 2011;10:56-68.
29. Morikawa K, Walker SM, Jessup JM, Fidler IJ. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 1988;48:1943-8.
30. van de Ven AL,WuM, Lowengrub J,McDougall SR,ChaplainMAJ, Cristini V, et al. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Advances 2012;2:11208.
31. Srinivasan S, Alexander JF, Driessen WH, Leonard F, Ye H, Liu X, et al. Bacteriophage associated silicon particles: design and characterization of a novel theranostic vector with improved payload carrying potential. J Mater Chem B Mater Biol Med 2013;1:5218-29.
32. Miyagawa S, Miwa S, Soeda J, Kobayashi A, Kawasaki S. Morphometric analysis of liver macrophages in patients with colorectal liver metastasis. Clin Exp Metastasis 2002;19:119-25.
33. European Medicines Agency. Nanoparticle albumin bound paclitaxel Annex 1-summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000778/WC500020435.pdf [accessed November 30, 2015].
34. Ferrati S,Mack A, Chiappini C, Liu X, Bean AJ, Ferrari M, et al. Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale 2010;2:1512-20.
35. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release 2013;170:365-72.
36. MaedaH,Wu J, Sawa T,Matsumura Y, Hori K.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.
37. Fu S, Naing A,Moulder SL, Culotta KS,Madoff DC, Ng CS, et al. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther 2011;10: 1300-7.
38. Bertino JR. Implantable pump for long-term chemotherapy administration via the hepatic artery: has it fulfilled its promise? J Clin Oncol 2008; 26:4528-9.
39. Higashi N, Ishii H, Fujiwara T, Morimoto-Tomita M, Irimura T. Redistribution of fibroblasts and macrophages as micrometastases develop into established liver metastases. Clin Exp Metastasis 2002; 19:631-8.
40. Bugelski PJ, Kirsh RL, Sowinski JM, Poste G. Changes in the macrophage content of lung metastases at different stages in tumor growth. Am J Pathol 1985;118:419-24.
41. Brain JD, Molina RM, DeCamp MM, Warner AE. Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species. Am J Physiol 1999;276:L146-54.
42. Warner AE, Brain JD. Intravascular pulmonary macrophages: a novel cell removes particles from blood. Am J Physiol 1986;250:R728-32.
43. van Rooijen N, Hendrikx E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 2010;605: 189-203.
44. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5 Suppl 6:S3-6.
45. Crofton RW, Diesselhoff-den Dulk MM, van Furth R. The origin, kinetics, and characteristics of the Kupffer cells in the normal steady state. J ExpMed 1978;148:1-17.
46. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 2010;28:181-8.
47. Pascal J, Bearer EL, Wang Z, Koay EJ, Curley SA, Cristini V. Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. Proc Natl Acad Sci U S A 2013;110:14266-71.